Search Results - Caroline Almon
- Showing 1 - 3 results of 3
-
1
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial by Mrinal M. Gounder, Melissa L. Johnson, Rebecca S. Heist, Geoffrey I. Shapiro, Sophie Postel‐Vinay, Frederick H. Wilson, Elena Garralda, Gerburg M. Wulf, Caroline Almon, Salah Nabhan, Elia Aguado-Fraile, Peng He, Mathilde Romagnoli, Mohammad Ismail Hossain, Rohini Narayanaswamy, Amel Sadou-Dubourgnoux, Michael K. Cooper, Vasileios Askoxylakis, Howard A. Burris, Josep Tabernero
Published 2025Artigo -
2
Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to... by Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Keith W. Pratz, Michael R. Savona, Anthony S. Stein, Richard M. Stone, Eric S. Winer, Christopher S. Seet, Hartmut Döhner, Daniel A. Pollyea, James McCloskey, Olatoyosi Odenike, Bob Löwenberg, Gert J. Ossenkoppele, Prapti A. Patel, Mikhail Roshal, Frederik Lersch, Salah Nabhan, Sung Choe, Hongfang Wang, Lei Hua, Caroline Almon, Michael K. Cooper, Martin S. Tallman
Published 2018Artigo -
3
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study by Eytan M. Stein, Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Keith W. Pratz, Michael R. Savona, Anthony S. Stein, Richard M. Stone, Eric S. Winer, Christopher S. Seet, Hartmut Döhner, Daniel A. Pollyea, James McCloskey, Olatoyosi Odenike, Bob Löwenberg, Gert J. Ossenkoppele, Prapti A. Patel, Mikhail Roshal, Mark G. Frattini, Frederik Lersch, Aleksandra Franovic, Salah Nabhan, Bin Fan, Sung Choe, Hongfang Wang, Bin Wu, Lei Hua, Caroline Almon, Michael K. Cooper, Hagop M. Kantarjian, Martin S. Tallman
Published 2020Artigo
Search Tools:
Related Subjects
Internal medicine
Medicine
Chemotherapy
Gastroenterology
Induction chemotherapy
Oncology
Surgery
Adverse effect
Amino acid
Anemia
Biochemistry
Biology
Chemistry
Chemotherapy regimen
Gene
Genetics
IDH1
IDH2
Methionine
Methionine Adenosyltransferase
Mutation
Myeloid leukemia
Pharmacodynamics
Pharmacokinetics
Pharmacology
Tolerability